[ Etude ]

Une étude américaine sur les effets sanitaires du Cannabis

Cancer

* The evidence suggests that smoking cannabis does not increase the risk for certain cancers
(i.e., lung, head and neck)
in adults.
* There is modest evidence that cannabis use is associated with one subtype of testicular cancer.
* There is minimal evidence that parental cannabis use during pregnancy is associated with greater cancer  risk in offspring.


Cardiometabolique


* The evidence is unclear as to whether and how cannabis use is associated with heart attack, stroke, and diabetes.

Respiratoire

* Smoking cannabis on a regular basis is associated with chronic cough and phlegm production.
* Quitting cannabis smoking is likely to reduce chronic cough and phlegm production.
* It is unclear whether cannabis use is associated with chronic obstructive pulmonary disorder, asthma,
or worsened lung function


Immunité

* There exists a paucity of data on the effects of cannabis or cannabinoid-based therapeutics on the human immune
system.
* There is insufficient data to draw overarching conclusions concerning the effects of cannabis smoke
or cannabinoids on immune competence.
* There is limited evidence to suggest that regular exposure to cannabis smoke may have anti-inflammatory activity.
* There is insufficient evidence to support or refute a statistical association between cannabis or cannabinoid use
and adverse effects on immune status in individuals with HIV

Accidents
        
* Cannabis use prior to driving increases the risk of being involved in a motor vehicle accident.
* In states where cannabis use is legal, there is increased risk of unintentional cannabis overdose injuries among children.
* It is unclear whether and how cannabis use is associated with all-cause mortality or with occupational injury.

Grossesse

* Smoking cannabis during pregnancy is linked to lower birthweight in the offspring.
* The relationship between smoking cannabis during pregnancy and other pregnancy and childhood outcomes is unclear.

Psychosocial

* Recent cannabis use impairs the performance in cognitive domains of learning, memory, and attention. Recent use may be defined as cannabis use within 24 hours of evaluation.
* A limited number of studies suggest that there are impairments in cognitive domains of learning, memory, and attention in individuals who have stopped smoking cannabis.
* Cannabis use during adolescence is related to impairments in subsequent academic achievement and education, employment and income, and social relationships and social roles.

Santé Mentale

* Cannabis use is likely to increase the risk of developing schizophrenia and other psychoses; the higher the use, the greater the risk.
* In individuals with schizophrenia and other psychoses, a history of cannabis use may be linked to better performance on learning and memory tasks.
* Cannabis use does not appear to increase the likelihood ofdeveloping depression, anxiety, and posttraumatic stress disorder.
* For individuals diagnosed with bipolar disorders, near daily cannabis use may be linked to greater symptoms of bipolar disorder than for nonusers.
* Heavy cannabis users are more likely to report thoughts of suicide than are nonusers.
* Regular cannabis use is likely to increase the risk for developing social anxiety disorder.

Problemes liés à la consommation du cannabis

* Greater frequency of cannabis use increases the likelihood of developing problem cannabis use.
* Initiating cannabis use at a younger age increases the likelihood of developing problem cannabis use.

Dépendance

Cannabis use is likely to increase the risk for developing substance dependence (other than cannabis use disorder).
nb= il y a une relation mais il ne semble pas y avoir de relation de causalité prouvée.

En effet, l’Académie rappelle qu’en ce qui concerne l’état des connaissances relatives au  cannabis et à  ses constituants, aucun progrès significatif dans le domaine de leurs intérêts thérapeutiques allégués n’est apparu récemment, alors que les connaissances de leurs effets adverses se sont précisées et multipliées.  L’évolution de la législation en faveur de leur inscription comme agents thérapeutiques ne  semble  pas  justifiée pour des raisons pharmaco-thérapeutiques.

Non seulement les bénéfices potentiels du THC sont tous modestes, sans exception, mais on dispose de vrais médicaments plus efficaces pour chacun des bénéfices attendus. En revanche, les risques que fait courir le  tétrahydrocannabinol / THC sont très nombreux, souvent graves et incompatibles avec un usage thérapeutique. Toutefois, on peut s’étonner, sur le plan pharmacologique, de voir associés le  THC, dans une proportion mal justifiée, et le CBD, au mécanisme d’action incertain, afin d’amoindrir les méfaits du THC.

Amicalement

Prescripteur a écrit

[...]voila ci dessous ce que dit l'Académie Française de Médecine.[...]

Petit conton a écrit

Sérieusement !?

Le cannabis à montrait sont efficacité dans bien des pathologies

Et celui si n'a pas tellement d'effets secondaires gênants

Je suis surpris d'un tel rapport

Perso, je suis tout sauf surpris :

> https://www.psychoactif.org/forum/t2428 … ml#p272507


Bien amicalement.